中国P站

Solid lipid nanoparticles; Oral bioavailability; Poorly soluble drugs; Nanocarriers; Anticancer therapy; Lipid-based delivery; Drug absorption; Gastrointestinal tract; Controlled release; Drug solubility enhancement

Introduction

Many promising anticancer agents suffer from poor aqueous solubility, leading to limited oral bioavailability and reduced therapeutic efficacy. Traditional oral formulations often fail to deliver sufficient drug concentrations to systemic circulation, resulting in variable absorption and compromised treatment outcomes [1-5]. Solid lipid nanoparticles (SLNs), composed of biocompatible lipids and stabilized by surfactants, offer a novel delivery platform to overcome these limitations. SLNs encapsulate hydrophobic drugs within a solid lipid matrix, enhancing solubility, protecting the drug from degradation, and enabling controlled release. Their nanometric size allows better adhesion to the gastrointestinal mucosa and increased lymphatic transport, bypassing first-pass metabolism. This study explores the formulation, characterization, and therapeutic benefits of SLNs for enhancing the oral delivery of poorly water-soluble anticancer drugs [6-10].

Discussion

SLNs provide a stable and versatile carrier system for lipophilic drugs. They offer numerous advantages, including enhanced permeability across intestinal epithelium, prolonged circulation time, and reduced systemic toxicity. For example, drugs like paclitaxel, docetaxel, and curcumin have shown improved oral bioavailability when delivered via SLNs. The lipid matrix not only solubilizes the drug but also protects it from gastric degradation. Furthermore, SLNs can be engineered with surface modifications such as PEGylation or ligand conjugation to improve mucosal adhesion and site-specific targeting. Pharmacokinetic studies reveal a marked increase in Cmax and AUC compared to traditional formulations, validating their clinical potential. However, challenges like scalability, drug loading efficiency, and long-term stability require further optimization. Advances in hot homogenization, solvent evaporation, and high-pressure emulsification have significantly improved reproducibility and particle size control. Toxicity assessments confirm SLNs’ safety, with minimal immunogenic response and high tolerability in preclinical models.

Conclusion

Solid lipid nanoparticles represent a promising strategy to improve the oral bioavailability of poorly soluble anticancer drugs. Their ability to enhance solubility, protect drugs from degradation, and ensure sustained release makes them valuable tools in oncology. Continued research on formulation techniques and clinical validation will pave the way for their widespread adoption. Ultimately, SLNs can help overcome one of the major limitations in oral chemotherapy and contribute to more effective and patient-friendly cancer treatments.

References

1. Sahin U (2020) Nature 585: 107-112.

   , ,

2. Alameh MG (2021) Immunity 54: 2877-2892.

   , ,

3. Islam MA (2021) . Biomaterials 266:120431.

   , ,

4. Van Hoecke L (2021) . Mol. Cancer 20:48.

   , ,

5. Pulendran B, Arunachalam PS, O'Hagan DT (2021) Nat. Rev. Drug Discov 20: 454-475.

   , ,

6. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J (2013) Journal of Gene Medicine 15: 65-77.

   , ,

7. Allen TM, Cullis PR. (2004) . Science 303: 1818-1822.

   , ,

8. Chakraborty C, Pal S, Doss GP, Wen Z, Lin C (2013) Frontiers in Bioscience 18: 1030-1050.

   , ,

9. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, et al. (2021) Drug Discov Today 26: 80-93.

   , ,

10. Sapoval N, Aghazadeh A, Nute MG (2022) Nat Commun 13

    , ,